COVID-19 Monoclonal Antibody Therapeutics Information for Providers

Casirivimab/imdevimab, bamlanivimab/etesevimab, and sotromivab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa. 

Find a COVID-19 Monoclonal Antibody Provider

HHS mAb Site Locator     NICA mAb Site Locator

Request COVID-19 Monoclonal Antibodies

Casirivimab/imdevimab, bamlanivimab/etesevimab and sotromivab are available at no cost to providers. Providers can submit a request to receive monoclonal antibodies here. By submitting a request, sites are required to:

  • Provide AmerisourceBergen with board of pharmacy license or physician letter of authorization
  • Attest to their designated class of trade and that they will administer authorized product according to the EUA
  • Provide utilization data via Teletracking or NHSN

 Additional information on the distribution process can be found here.


General Resources

Bamlanivimab/Etesevimab (Eli Lilly)

Casirivimab/Imdevimab (Regeneron)

Sotromivab (GSK)